Neuraxis, Inc.

NRXS

Neuraxis, Inc. (NRXS) is a biotechnology company focused on developing neurotherapeutic products targeting neurological and psychiatric disorders. The company specializes in creating innovative treatments leveraging its expertise in neurostimulation and neurotechnology to address unmet medical needs in neurological conditions.

$2.65 +0.03 (1.15%)
🚫 Neuraxis, Inc. does not pay dividends

Company News

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
GlobeNewswire Inc. • Neuraxis, Inc. • October 24, 2025

NeurAxis received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) technology to treat functional dyspepsia and related nausea symptoms in patients aged 8 years and older, marking the first FDA approval for this condition in adults.

Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga • Lisa Levin • September 12, 2023

Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. Avalo Therapeutics, Inc. (NASDAQ: AVTX) gained 52.6% to $0.1295 after the company agreed to divest AVTX-800 series. Shengfeng Development Limited (NASDAQ: SFWL) rose...

OCTOACBSGHTIVPLAWXOS

Related Companies

NRX Pharmaceuticals, Inc. Common Stock
NRX Pharmaceuticals, Inc. Common Stock
NRXP
NRX Pharmaceuticals, Inc. Warrant
NRX Pharmaceuticals, Inc. Warrant
NRXPW
National Storage Affiliates Trust 6.000 Percent Series A Cumulative Redeemable Preferred Shares of Beneficial Interest (Liquidation Preference $25.00 per share)
NSApA
National Storage Affiliates Trust
National Storage Affiliates Trust
NSA